GemCyclo Bio
Leading the Era of Oral Cyclic Peptides
Company Overview
Snapshot
Founded in March 2025 by Doron Friedman and Oron Yacoby - Zeevi, GemCyclo Bio operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on developing novel orally available cyclic peptides.
Business overview
GemCyclo Bio is an early-stage biopharmaceutical company specializing in the development of innovative new drugs. The company holds a library of novel orally available cyclic peptides designed to target validated molecular pathways associated with immune and inflammatory diseases, cancer, and metabolic diseases. Utilizing proprietary Cycloscan technology licensed from the Hebrew University of Jerusalem, GemCyclo Bio designs and synthesizes highly potent and metabolically stable small cyclic peptides, enabling multiple routes of administration. These novel peptides combine the ease of synthesis and low immunogenicity of small molecules with the high affinity and selectivity of monoclonal antibodies, aiming for low off-target toxicity.
Company Intelligence Q&A
- When was GemCyclo Bio founded?
- GemCyclo Bio was founded in March 2025.
- Who are the co-founders of GemCyclo Bio?
- The co-founders of GemCyclo Bio are Doron Friedman and Oron Yacoby - Zeevi.
- What is GemCyclo Bio's primary focus?
- GemCyclo Bio is focused on developing novel orally available cyclic peptides for immune and inflammatory diseases, cancer, and metabolic diseases.
- What technology does GemCyclo Bio utilize?
- GemCyclo Bio utilizes proprietary Cycloscan technology, licensed from the Hebrew University of Jerusalem, for designing and synthesizing cyclic peptides.
- What is the current stage of GemCyclo Bio?
- GemCyclo Bio is currently in the Pre-Funding stage.